2023 State of Tech in Biopharma report reveals tech methods in period of information and AI 

Benchling has launched its inaugural 2023 State of Tech in Biopharma report, which has make clear the obstacles that biopharma encounter when striving to completely implement and embrace these applied sciences. 

The report surveyed 300 R&D and IT specialists from biopharma corporations massive and small to do a first-ever investigation into biopharma’s use of an enabling tech stack — consisting of robotics and automation, linked devices, R&D knowledge platforms, cloud-based scientific functions, and AI and ML.

The report finds that the biopharma business is broadly adopting enabling tech, with R&D knowledge platforms essentially the most broadly adopted (at 70%), adopted by robotics and automation platforms (63%), AI and ML (59%). Nonetheless, the adoption of SaaS software program is lagging, with solely 18% of respondents utilizing it for almost all of their R&D and IT work. 

This excessive tech adoption has additionally corresponded with a posh tech surroundings in labs — with 53% of scientists utilizing 5+ distinctive scientific software program functions every day, and 40% of IT at massive corporations supporting greater than 20 functions. 84% are utilizing some custom-built software program, indicating a holdover of legacy programs. As well as, 41% of scientists discover collaborating with and throughout groups a problem, and 38% are needing to collaborate with 20 or extra individuals of their day-to-day work.  

With such complexity, FAIR knowledge ideas are nonetheless out of attain – with restricted progress in attaining organisation-wide knowledge interoperability (I) at 28%, and knowledge reusability (R) at 30%. 

The report additionally reveals that the 2 largest boundaries to adopting enabling tech and with the ability to work with it successfully is a scarcity of expert expertise, and science-specific options. This reveals a transparent name to motion for the business to put money into attracting the appropriate expertise to work with rising applied sciences, and those that have a robust want to construct new, fit-for-purpose scientific software program that may delight scientists and release IT groups.  

Benchling’s analysis reveals corporations additionally must take a logical step of fostering stronger alignment between their R&D and IT organisations — together with rationalising divergent tech priorities and having an sincere dialogue on the true boundaries to adoption, similar to organisational tradition and alter administration. Within the coming years, the significance of scientific knowledge and AI will solely develop, placing further stress on biopharma to desert legacy tech and construct a stronger digital basis. 

Bob Burke, EMEA GM at Benchling, mentioned: “We’re witnessing a exceptional period in biopharma, the place groundbreaking therapies and technological improvements are reshaping illness prevention and therapy. Enabling tech helps corporations deliver the facility of automation, cloud, and AI to bear on issues of velocity, high quality, success, and scalability in biopharma.

“Our report highlights the hurdles that have to be surmounted to speed up scientific progress. Within the years forward, scientific knowledge and AI will achieve even better significance, intensifying the necessity for biopharma to shed legacy tech and fortify its digital basis. Firms able to attracting prime expertise, fostering alignment between R&D and IT, and swiftly adopting new applied sciences, the appropriate applied sciences that are constructed for this new period of biology, are poised to turn out to be essentially the most influential gamers in biopharma, driving success for generations to come back”. 

“To propel the UK towards its science superpower imaginative and prescient, it’s crucial that we entice extra technical expertise to the life sciences business, upskill and prepare current staff, and prioritise user-friendly and built-for-biology SaaS and tech instruments. Expertise is right here and the roots are right here however we have to do a greater job of connecting the dots between tech innovation and the chance in life sciences.”  

About Benchling 

Benchling is the pioneer of the R&D Cloud, software program that unlocks the facility of biotechnology. Greater than 200,000 scientists at over 1,200 corporations and seven,500 tutorial and analysis establishments globally have adopted the Benchling R&D Cloud to make breakthrough discoveries and produce the following era of medicines, meals, and supplies to market quicker. The Benchling R&D Cloud helps these organisations modernise their scientific processes and speed up collaboration to allow them to convert the complexity of biology into world-changing outcomes. For extra, please go to Benchling.com.  

Methodology  The report is predicated on a web based survey performed from July thirteenth to August 1st, with 300 respondents from the prescribed drugs and biotechnology business. Respondents included 59% from R&D and 41% from IT, with 55% from massive corporations and 45% from small corporations.

Wish to be taught extra about cybersecurity and the cloud from business leaders? Take a look at Cyber Security & Cloud Expo going down in Amsterdam, California, and London. Discover different upcoming enterprise know-how occasions and webinars powered by TechForge here.

Tags: AI, biopharma, ML, platforms